Recent Investment Analysts’ Ratings Changes for Twist Bioscience (TWST)

Several analysts have recently updated their ratings and price targets for Twist Bioscience (NASDAQ: TWST):

• 10/8/2026 – Twist Bioscience is now covered by Jefferies Financial Group Inc.. They set a “hold” rating and a $150.00 price target on the stock.
• 10/7/2026 – Twist Bioscience had its price target raised by Barclays PLC from $112.00 to $215.00. They now have an “overweight” rating on the stock.
• 10/1/2026 – Twist Bioscience had its price target raised by Guggenheim from $107.00 to $212.00. They now have a “buy” rating on the stock.
• 9/29/2026 – Twist Bioscience had its price target raised by Leerink Partners from $160.00 to $190.00. They now have an “outperform” rating on the stock.
• 9/21/2026 – Twist Bioscience had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/18/2026 – Twist Bioscience had its “sell” rating reaffirmed by BWS Financial. They now have a $45.00 price target on the stock.
• 9/17/2026 – Twist Bioscience had its price target raised by Leerink Partners from $120.00 to $160.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Twist Bioscience is now covered by BWS Financial. They set a “sell” rating and a $45.00 price target on the stock.
• 9/9/2026 – Twist Bioscience is now covered by UBS Group AG. They set a “neutral” rating and a $144.00 price target on the stock.
• 8/24/2026 – Twist Bioscience had its “buy” rating reaffirmed by Guggenheim.

Insider Transactions at Twist Bioscience

In related news, insider Dennis Cho sold 9,514 shares of Twist Bioscience stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $188.88, for a total value of $1,797,004.32. Following the sale, the insider owned 63,789 shares of the company’s stock, valued at approximately $12,048,466.32. The trade was a 12.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Robert Werner sold 1,482 shares of the stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $279,920.16. Following the transaction, the chief accounting officer directly owned 42,917 shares of the company’s stock, valued at $8,106,162.96. This trade represents a 3.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 599,458 shares of company stock worth $93,383,392. 3.08% of the stock is owned by insiders.

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.